Clarus Therapeutics, Inc. is a men's specialty pharmaceutical company with a mission to help men with hypogonadism, a condition associated with a deficiency or absence of endogenous testosterone. We are working hard every day to make a difference in the lives of affected men.
As a privately-held company, Clarus Therapeutics is backed by Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd.
To learn more, visit clarustherapeutics.com.
View our community guidelines: http://bit.ly/2H9QmH5
As a privately-held company, Clarus Therapeutics is backed by Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd.
To learn more, visit clarustherapeutics.com.
View our community guidelines: http://bit.ly/2H9QmH5
Location: Canada, Ontario, Northbrook
Employees: 11-50
Total raised: $30M
Founded date: 2004
Investors 3
| Date | Name | Website |
| - | H.I.G. Cap... | higcapital... |
| - | H.I.G. Bio... | higbio.com |
| - | CBC Group | cbridgecap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.04.2022 | - | $30M | - |
Mentions in press and media 6
| Date | Title | Description |
| 19.08.2022 | Covid-19 roundup: EMA starts review of SK’s vaccine; Australian biotech switching gears away from Covid research | The clock is ticking for penny stock biotech Clarus Therapeutics. With $19.2 million left in the bank and $40.5 million of senior notes payable, the company is pulling out all the stops to stay afloat — axing 40% of its workforce and closin... |
| 27.04.2022 | Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering | NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies f... |
| 25.04.2022 | Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering | NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies f... |
| 25.05.2021 | Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer | |
| 27.04.2021 | Blue Water Acquisition : Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Development Of Androgen And Metabolic Th... | NORTHBROOK, Ill. and GREENWICH, Conn., April 27, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therap... |
| 27.04.2021 | BLUE WATER ACQUISITION CORP. Blue Water Acquisition : Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Developmen... | NORTHBROOK, Ill. and GREENWICH, Conn., April 27, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therap... |